Legend Biotech (LEGN) Amortization of Deferred Charges (2020 - 2025)

Legend Biotech's Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $4.0 million for Q3 2025.

• Quarterly Amortization of Deferred Charges rose 42.64% year-over-year to $4.0 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $13.0 million (up 43.79% YoY) and the FY2022 annual result came in at $5.7 million, up 30.55% from the prior year.
• Amortization of Deferred Charges was $4.0 million for Q3 2025 at Legend Biotech, up from $3.5 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $5.7 million in Q4 2022 and bottomed at $257000.0 in Q1 2022.
• A 5-year average of $2.2 million and a median of $2.2 million in 2024 frame the typical range for Amortization of Deferred Charges.
• Peak annual rise in Amortization of Deferred Charges reached 525.21% in 2022, while the deepest fall reached 29.4% in 2022.
• Legend Biotech's Amortization of Deferred Charges stood at $4.4 million in 2021, then surged by 30.55% to $5.7 million in 2022, then sank by 65.23% to $2.0 million in 2023, then surged by 39.06% to $2.8 million in 2024, then jumped by 42.64% to $4.0 million in 2025.
• Business Quant data shows LEGN's Amortization of Deferred Charges at $4.0 million in Q3 2025, $3.5 million in Q2 2025, and $2.8 million in Q1 2025.